Such a pleasure to work with Mackay Lab to study the genomic programming of tissue-resident memory T cells! Incredible amount of work led by Raissa Fonseca and Frank Buquicchio

🧬🔎Thrilled to share our latest findings on the epigenetic changes that occur post memory T cell development! Out today in Immunity! Incredible work led by Raissa Fonseca and Frank Buquicchio from team Ansu Satpathy! 🧵👇 Doherty Institute @Unimelb Stanford University cell.com/immunity/abstr…

terrific review on a promising avenue for cancer immunotherapies, from the Masters

On bioRxiv today, we raise serious concerns over a recent @nature paper describing ReDeeM, a new single-cell mitochondrial DNA (mtDNA) sequencing / analysis method. Here are three things that you need to know: 1/n biorxiv.org/content/10.110…

Love this approach Dana-Farber Parker Institute for Cancer Immunotherapy

I am proud, pleased, and relieved to announce that the Schenkel Lab’s first paper is officially published J Immunol! This has been a labor of love and I think will be an useful for many in the field! journals.aai.org/jimmunol/artic… 1/n

A massive thank you to everyone for their feedback on the commentary, particularly those who have followed up about their experiences with their own ReDeeM data. I want to add a couple of forward-looking points: 1/n

Very happy to share this new work on LAG3 and PD1. Has been a long road to (begin to) sort out how LAG3 functions in CD8 T cell exhaustion. Great work by Shin Ngiow and super collaboration (and 2 other great papers) with Vignali Lab and Dario Vignali cell.com/cell/abstract/…

500+ CD19 Assets!!!! 😳😳😳😳 WHAT WILL HAPPEN TO THEM ALL? 👇🏼Here is a long form tweet using PD-1 as an example to let history answer the question TLDR: 🔘Most will fail during clinical trials 🔘Some will not gain regulatory approval 🔘Some will struggle commercially 🔘Some

Indeed: finding and optimizing drugs in rudimentary in vitro assays is like “finding the best sprinter and sending them to run a marathon” Thank you nature Biotechnology and Michael Eisenstein for featuring our work in this great piece. As Michael elegantly outlines, we at Vevo

Our new #paper is out in Nature Immunology. Applying #spatial transcriptomics at subcellular resolution to 130 ovarian #cancer tumors, followed by data-driven experimental design and high content #CRISPR screens to map immune evasion in ovarian cancer nature.com/articles/s4159… (1/15)

Long-term ART was associated with a process of clonal succession, which effectively rejuvenated HIV-1-specific CD8+ T cell populations in the face of immune senescence Nature Immunology nature.com/articles/s4159…

Dendritic cells were always my first love. Great to read this study from Keiji Hirota and team using better tools to conclusively resolve a long-standing debate on whether DCs or macrophages are the critical producers of IL-23 in inflammation. Katha Lahl Isabel Ulmert JExpMed

Excited to share the white paper for the IGVF Consortium, supported by National Human Genome Research Institute Deciphering the impact of genomic variation on function rdcu.be/dSZdm

Our single-cell, pan-cancer analysis of open chromatin in human cancers, done in collaboration with TCGA and the Chang and Corces labs (among others including Illumina), is out in Science today. Congrats to Laksshman Sundaram and all authors! science.org/doi/10.1126/sc…

One of the last stories from my postdoc work with Howard Chang and William J. Greenleaf is out today Science Magazine led by Laksshman Sundaram. scATAC-seq of 8 different tumor types from TCGA. science.org/doi/10.1126/sc…

The news that Summit Therapeutics cancer drug beat Keytruda head-to-head has the company's stock up 17% in pre-market trading. What makes this story even more amazing, astounding, unusual are the two people most behind it: co-CEOs Bob Duggan and Maky Zanganeh, who were also